Literature DB >> 21220035

Comparison between matched related and alternative donors of allogeneic hematopoietic stem cells transplanted into adult patients with acquired aplastic anemia: multivariate and propensity score-matched analysis.

Hawk Kim1, Byung Soo Kim, Dong Hwan Kim, Myung Soo Hyun, Sung Hyun Kim, Sung Hwa Bae, Jung Hye Choi, Sang Kyun Sohn, Ho Jin Shin, Jong Ho Won, Sung-Soo Yoon, Deog-Yoen Jo, Young Don Joo, Jae-Hoo Park, Kyoo-Hyung Lee.   

Abstract

We retrospectively compared the outcomes of 225 patients with adult acquired aplastic anemia (AA) who underwent allogeneic hematopoietic stem cell transplantation (alloHSCT) from matched related donors (MRDs), and those treated by alloHSCT from alternative donors (ADs). Univariate and multivariate analyses of factors associated with survival were performed. Multivariate analysis showed that age at alloHSCT of ≤ 31 years, MRD, successful engraftment, absence of acute graft-versus-host disease (aGVHD), and platelet engraftment at ≤ 21 days, were independent predictors of longer survival. In addition, time to aGVHD and cumulative nonrelapse mortality (NRM) were better in MRD than in AD recipients. Using propensity score matching (PSM), we performed a case-control study comparing 25 patients in each group who underwent alloHSCT from MRDs and ADs. Pretransplantation clinical factors were well balanced in either group. Median survival time was similar, and no statistically significant difference in transplantation outcomes was apparent when MRD and AD recipients were compared. In conclusion, our results suggest that alloHSCT from an AD should be considered earlier in adult patients with AA who do not have an MRD.
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21220035     DOI: 10.1016/j.bbmt.2010.12.715

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  6 in total

Review 1.  How I treat acquired aplastic anemia.

Authors:  Phillip Scheinberg; Neal S Young
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

2.  Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.

Authors:  Gheath Alatrash; Kelly M Kidwell; Peter F Thall; Antonio Di Stasi; Julianne Chen; Madhushree Zope; Alyssa K Crain; Richard E Champlin; Uday Popat; Elizabeth J Shpall; Roy B Jones; Borje S Andersson
Journal:  Bone Marrow Transplant       Date:  2018-12-10       Impact factor: 5.483

3.  Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia.

Authors:  Zhi Guo; Hong-Yan Gao; Tian-Yan Zhang; Xiao-Dong Liu; Kai Yang; Jing-Xing Lou; Xue-Peng He; Yuan Zhang; Peng Chen; Hui-Ren Chen
Journal:  Int J Hematol       Date:  2016-10-05       Impact factor: 2.490

Review 4.  Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions.

Authors:  Aaron T Gerds; Bart L Scott
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

5.  Primary Immune Deficiency Treatment Consortium (PIDTC) report.

Authors:  Linda M Griffith; Morton J Cowan; Luigi D Notarangelo; Donald B Kohn; Jennifer M Puck; Sung-Yun Pai; Barbara Ballard; Sarah C Bauer; Jack J H Bleesing; Marcia Boyle; Amy Brower; Rebecca H Buckley; Mirjam van der Burg; Lauri M Burroughs; Fabio Candotti; Andrew J Cant; Talal Chatila; Charlotte Cunningham-Rundles; Mary C Dinauer; Christopher C Dvorak; Alexandra H Filipovich; Thomas A Fleisher; Hubert Bobby Gaspar; Tayfun Gungor; Elie Haddad; Emily Hovermale; Faith Huang; Alan Hurley; Mary Hurley; Sumathi Iyengar; Elizabeth M Kang; Brent R Logan; Janel R Long-Boyle; Harry L Malech; Sean A McGhee; Fred Modell; Vicki Modell; Hans D Ochs; Richard J O'Reilly; Robertson Parkman; David J Rawlings; John M Routes; William T Shearer; Trudy N Small; Heather Smith; Kathleen E Sullivan; Paul Szabolcs; Adrian Thrasher; Troy R Torgerson; Paul Veys; Kenneth Weinberg; Juan Carlos Zuniga-Pflucker
Journal:  J Allergy Clin Immunol       Date:  2013-10-15       Impact factor: 10.793

6.  Human embryonic stem cell therapy for aplastic anemia.

Authors:  Geeta Shroff; Rakesh Gupta; Lalduhawmi Zadeng
Journal:  Clin Case Rep       Date:  2017-04-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.